WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 200.59B +45.7% |
| Revenue (ttm) | 27.27B +17.8% |
| Net Income | 5.78B +19.4% |
| EPS | 1.37 +19.8% |
| Shares Out | 4.10B |
| PE Ratio | 35.75 |
| Forward PE | 24.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,180,299 |
| Open | 48.74 |
| Previous Close | 49.62 |
| Day's Range | 47.02 - 49.86 |
| 52-Week Range | 28.48 - 58.00 |
| Beta | 0.59 |
| Analysts | Strong Buy |
| Price Target | 60.25 (+23.26%) |
| Est. Earnings | Nov 25, 2026 |
About WuXi Biologics
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and ... [Read more]
Financial Performance
In 2025, WuXi Biologics's revenue was 21.79 billion, an increase of 16.68% compared to the previous year's 18.68 billion. Earnings were 4.91 billion, an increase of 46.25%.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for 2269 stock is "Strong Buy." The 12-month stock price target is $60.25, which is an increase of 23.26% from the latest price.
News
WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence
HONG KONG, Nov. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two Grand Awards a...
Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
Exclusive option rights for up to 37 potential first-to-market biosimilar candidates to significantly expand Fresenius' portfolio from 29 marketed and pipeline molecules today to up to 66 in the next ...
Fresenius, WuXi Enter Development Agreement To Expand Biosimilars Pipeline
(RTTNews) - Fresenius SE & Co. KGaA has entered an exclusive development agreement with WuXi Biologics (2269.HK), which provides Fresenius access to up to 37 identified biosimilar candidates over the ...
WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026
Also Named Best in Transition (Hong Kong) Recognized for ESG Leadership and Green and Digital Transformation SHANGHAI, Oct. 21, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract...
WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence
• Inclusion in the Hang Seng ESG 50 Index, signifying continued capital-market recognition of the Company's ESG performance • Inclusion in the Hang Seng Corporate Sustainability Benchmark Index, refle...
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability
WUXI, China, Sept. 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its drug substance (DS) and...
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
SHANGHAI, Sept. 16, 2026 /PRNewswire/ -- Forbes China recently released the 2026 Forbes China ESG 50 list.
Big Pharma Is Pouring Billions Into China's Biotechs
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.
Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies
PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discover...
WuXi Biologics price target raised to HK$62 from HK$51.10 at UBS
UBS raised the firm’s price target on WuXi Biologics (WXIBF) to HK$62 from HK$51.10 and keeps a Buy rating on the shares. Following a strong 1H26 result, the firm raised…
WuXi Biologics Earnings Call Transcript: H1 2026
Revenue grew 18.4% year-over-year, with gross margin up to 46.2% and adjusted net profit rising 38.6%. The portfolio is increasingly weighted toward high-margin ADCs and bispecifics, driving margin expansion and robust backlog growth. Guidance was raised, with revenue expected to grow 20%-23% in constant currency.
WuXi Biologics Earnings release: H1 2026
WuXi Biologics released its H1 2026 earnings on August 26, 2026, summarizing the period's financial results.
WuXi Biologics Slides: H1 2026
WuXi Biologics has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 26, 2026.
WuXi Biologics Quarterly report: H1 2026
WuXi Biologics has published its H1 2026 quarterly earnings report on August 26, 2026.
WuXi Biologics Reports Strong Profitable Growth in H1 2026
Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD) IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite forei...
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- BioPharma APAC recently published its Top 26 - Companies Leading Sustainable Biopharma Practices in 2026 , highlighting leading sustainability practices across ...
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
SHANGHAI, July 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in ...
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) Included in the MSCI ESG Selection Indexes for the fourth consecutive year Leader in Green...
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facili...
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Cent...
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site w...
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping ou...
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
SHANGHAI, June 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the ...
WuXi Biologics Transcript: Investor update
PatroLab and TrueSite technologies are driving automation and cost reductions, while project momentum remains strong with a 50% YoY increase and expanded capacity. Revenue growth guidance is reaffirmed at 13%-17% (16%-20% ex-FX), with manufacturing and biosimilar segments set for rapid expansion.
WuXi Biologics Slides: Investor update
WuXi Biologics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.